Virtus ETF Advisers LLC Takes $297,000 Position in Kalvista Pharmaceuticals Inc (NASDAQ:KALV)
Virtus ETF Advisers LLC purchased a new stake in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 13,395 shares of the specialty pharmaceutical company’s stock, valued at approximately $297,000. Virtus ETF Advisers LLC owned approximately 0.08% of Kalvista Pharmaceuticals at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in shares of Kalvista Pharmaceuticals by 3.2% during the 2nd quarter. Wells Fargo & Company MN now owns 35,710 shares of the specialty pharmaceutical company’s stock valued at $791,000 after purchasing an additional 1,103 shares in the last quarter. Bank of Montreal Can grew its position in shares of Kalvista Pharmaceuticals by 28.5% during the 1st quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock valued at $166,000 after purchasing an additional 1,292 shares in the last quarter. Strs Ohio purchased a new position in shares of Kalvista Pharmaceuticals during the 2nd quarter valued at $68,000. Marshall Wace North America L.P. purchased a new position in shares of Kalvista Pharmaceuticals during the 1st quarter valued at $175,000. Finally, Swiss National Bank purchased a new position in shares of Kalvista Pharmaceuticals during the 2nd quarter valued at $390,000. Hedge funds and other institutional investors own 82.98% of the company’s stock.
NASDAQ:KALV traded down $0.34 during midday trading on Friday, hitting $15.26. The company had a trading volume of 42,366 shares, compared to its average volume of 74,454. Kalvista Pharmaceuticals Inc has a 52-week low of $14.50 and a 52-week high of $34.92. The stock’s fifty day moving average price is $15.96 and its 200-day moving average price is $21.35. The company has a market capitalization of $271.93 million, a PE ratio of -11.06 and a beta of 2.11. The company has a quick ratio of 6.40, a current ratio of 8.29 and a debt-to-equity ratio of 0.01.
A number of research analysts have recently commented on KALV shares. Leerink Swann started coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, July 29th. They set an “outperform” rating and a $31.00 price target for the company. BidaskClub lowered shares of Kalvista Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Roth Capital set a $30.00 price target on shares of Kalvista Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, September 6th. TheStreet lowered shares of Kalvista Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Thursday, July 11th. Finally, ValuEngine lowered shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Kalvista Pharmaceuticals presently has an average rating of “Buy” and an average price target of $29.86.
In other Kalvista Pharmaceuticals news, CEO Thomas Andrew Crockett sold 10,000 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the sale, the chief executive officer now directly owns 248,510 shares of the company’s stock, valued at $4,234,610.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Albert Cha purchased 26,500 shares of the stock in a transaction on Friday, July 26th. The stock was acquired at an average cost of $16.83 per share, with a total value of $445,995.00. The disclosure for this purchase can be found here. Insiders purchased 145,427 shares of company stock valued at $2,515,550 over the last quarter. 21.60% of the stock is owned by company insiders.
Kalvista Pharmaceuticals Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: Why Invest in Dividend Achievers?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.